Invectys publishes positive clinical results for its INVAC-1 Phase I Study in Clinical Cancer Research With an extended Phase I and a new delivery method…
A DNA vaccine targeting a specific cancer marker Cancer cells produce an enzyme which is key to their unlimited proliferation, but is nearly never expressed in normal…
Invectys announces FDA approval to launch a Phase II clinical trial of its therapeutic cancer vaccine INVAC-1 After a recent capital raise of 4.3 M€s another…
Medicen Paris Region et Invectys annoncent le succès du projet TelVac pour la recherche d’un candidat vaccin contre le cancer…
